Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
Are combination therapies more effective for the treatment of relapsed refractory CLL?
Immunotherapy highlights in multiple myeloma at ASH 2016
Niels van de Donk
Minimal residual disease (MRD) monitoring for multiple myeloma is here to stay
Which treatments are currently available for relapsed and refractory myeloma treatment?